Gene delivery technology: Adeno-associated virus

Pharmaceutical Gene Delivery Systems

Volumn , Issue , 2003, Pages 183-213

  Carter, Barrie J ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4344691292     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (144)

1. Flotte TR, Carter BJ, Conrad CK, Guggino WB, Reynolds TC, Rosenstein BJ, Taylor G, Walden S, Wetzel R: A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7: 1145-1159.
2. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg A, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109:266-274.
3. Kay MA, Manno CS, Rogni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chen AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallen C, Skarsgard E, Flake AW, High KA: Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat Genet 2000; 24:257-261.
4. Stedman H, Mendell J, Wilson JM, Finke R, Kleckner A-L: Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy with a-, ß-, Y-, or S-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Thera 2000; 11:777-790.
5. Carter BJ. Adeno-associated virus and adeno-associated virus vectors for gene delivery. In: Templeton NS and Lasic DD, eds. Gene Therapy: Therapeutic Mechanisms and Strategies. New York: Marcel Dekker, 2000, pp 41-49.
6. Carter BJ. The growth cycle of adeno-associated virus. In: Tjissen P, ed. Handbook of Parvoviruses. Vol 1. Boca Raton, FL: CRC Press, 1989; pp 155-168.
7. Berns KI. AAV Replication. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990, pp 1743-1764.
8. Carter BJ. Parvoviruses as vectors. In: Tjissen T, ed. Handbook of Parvoviruses. Vol 2. Boca Raton, FL: CRC Press, 1989, pp 247-284.
9. Muzyczka N. Use of Adeno-associated virus as a generalized transduction vector in mammalian cells. Curr Topics Microbiol Immunol 1992; 158:97-129.
10. Berns KI, Giraud C. Adeno-associated virus (AAV) vectors in gene therapy. Curr Topics Microbiol Immunol 1996, pp 1-171.
11. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotechnol 1992; 3:533-539.
12. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2:357-362.
13. Hallek M, Girod A, Braun-Flaco M, Clemens-Martin W, Bogedin C, Horer M. Recombinant adeno-associated virus vectors. Curr Res Mol Therapeut 1998; 1: 417-430.
14. Rabinowitz JE, Samulski R. Adeno-associated virus expression systems for gene transfer. Curr Opin in Biotechnol 1998; 9:470-475.
15. Summerford C, Samulski RJ. Adeno-associated viral vectors for gene therapy. Biogenic Amines 1998; 14:451-475.
16. Rabinowitz JE, Samulski RJ: Building a better vector: Manipulation of AAV virions Virology 2000; 278:301-308.
17. Blacklow NR. Adeno-associated viruses of humans. In: Pattison JR, ed. Parvoviruses and Human Disease. Boca Raton, FL: CRC Press, 1988, pp 165-174.
18. Carter BJ: Adeno-associated virus helper functions. In: (Tjissen P, ed.) Handbook of Parvoviruses. Vol 1. Boca Raton, FL: CRC Press, 1990, pp 255-282.
19. Carter BJ, Mendelson E, Trempe, JP:AAV DNA replication, integration and genetics. In: Tjissen P, ed. Handbook of Parvoviruses. Vol 1. Boca Raton, FL: CRC Press, 1989, pp 169-226.
20. Carter BJ. The promise of adeno-associated virus vectors. Nat Biotechnol 1996; 14:1725-1726.
21. Redemann B, Mendelson E, Carter BJ. Adeno-associated virus rep protein synthesis during productive infection. J Virol 1998; 63:873-882.
22. Myers MW and Carter BJ. 1980. Adeno-associated virus assembly. Virology 1980; 102:71-82.
23. Samulski RJ, Berns KI, Tan N, Muzyczka N. Cloning of infectious adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79:2077-2081.
24. Laughlin CA, Tratschin JD, Coon H, Carter BJ. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 1983; 23:65-73.
25. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI. Site-specific integration by adeno- associated virus. Proc Natl Acad Sci USA 1990; 87:2211-2215.
26. Samulski RJ, Zhu X, Xiao S, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EmBo j 1991; 10:3941.
27. McLauglin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structure. J Virol 1988; 62:1963-1973.
28. Weitzman, MD, Kyostio, SRM, Kotin, RM, and Owens, RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994; 91:5808-5812.
29. Kearns WG, Afione SA, Fulmer SB, Pang MG, Erikson D, Egan L, Landrum MJ, Flotte TR, Cutting GR. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996; 3:748-755.
30. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1996; 93:11288-11294.
31. Young SM, McCarty DM, Degtyareva N, Samulski RJ. Role of adeno-associated virus rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74:3953-3966.
32. Yakobson B, Koch T, Winocour E. Replication of adeno-associated virus in synchronized cells without the addition of helper virus. J Virol 1987; 61:972-981.
33. Yakobson B, Hrynko TA, Peak, MJ, Winocour, E. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol 1988; 63:1023-1030.
34. Bantel-Schaal U. and zur Hausen H. Adeno-associated viruses inhibit SV40 DNA amplification and replication of herpes simplex virus in SV40-transformed hamster cells. Virology 1988; 164:64-74.
35. Flotte TR, Zeitlin PL, Solow, Afione S, Owens RA, Markakis D, Drumm M, Gug-gino WB, Carter BJ. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268: 3781-3790.
36. Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000; 74:8732-8739.
37. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997; 4:16-24.
38. Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94:6916-6921.
39. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70:8098-8108.
40. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne B. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93:14082-14087.
41. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ. Atkinson M, Flotte TR. Sustained secretion of human alpha-l-antitryp-sin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95:14384-14388.
42. Yang Q, Chen F, Trempe JP. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J Virol 1994; 68:4847-4856.
43. Allen JA, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homolo-gous recombination during AAV vector production. J Virol 1997; 71:6816-6822.
44. Wang XS, Khuntirat B, Qing K, Ponnazhagan S, Kube DM, Zhou S, Dwarki VJ, Srivastava A. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998; 72:5472-5480.
45. Fan, P-D, Dong, J-Y. Replication of rep-cap genes is essential or the high-efficiency production of recombinant AAV. Hum Gene Ther 1997; 8:87-98.
46. Vincent, K, Piraino, ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene poducts. J Virol 1997; 71: 1897-1905.
47. Li, J, Samulski, RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71:5236-5243.
48. Xiao, X, Li, J, Samulski, RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72:2224-2233.
49. Matushita, T, Elliger, S, Elliger, C, Podskaoff, G, Villareal, Kurtzman, GJ, Iwaki, Y, Colosi, P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5:938-945.
50. Grimm, D, Kern, A, Rittnet, K, Kleinschmidt, JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998; 9:2745-2760.
51. Samulski RJ, Chang LS, Shenk TE. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63:3822-3828.
52. Flotte TR, Barrazza-Ortiz X, Solow R, Afione SA, Carter BJ, Guggino WB. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther 1995; 2:39-47.
53. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6:1329-1341.
54. Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR. Selective rep-cap gene amplifications as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2000; 2:394-403.
55. Gao, G-P, Qu, G, Faust, LZ, Engdahl, RK, Xiao, W, Hughes JV, Zoltick, PW, Wilson JM. High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9:2353-2362.
56. Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant virus. Gene Ther 1999; 6:293-299.
57. Inoue I, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J Virol 1998, 72:7024-7031.
58. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing rep and cap. J Virol 1997; 71: 8780-8789.
59. Conway JE, Rhys CMJ, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type 1 vector expressing AAV-2 rep and cap. Gene Ther 1999; 6:86-993.
60. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7;2079-2087.
61. Lieber A, Steinwarder DS, Carlson CA, Kay MA. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all genes. J Virol 1999; 73:9314-9324.
62. Sandolon Z, Gnatenko DM, Bahou WF, Hearing P. Adeno-associated (AAV) rep protein enhances the generation of a recombinant mini-adenovirus utilizing an Ad/AaV hybrid virus. J Virol 2000; 74:10381-10389.
63. Johnston, KM, Jacoby D, Pechan, PA, Fraefel, C, Borghesani, P, Schuback, D, Dunn, RJ, Smith, FI, Breakfield, O. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gen Ther 1997; 8:359-370.
64. Cao L, Liu Y, During M, Xiao W. High-titer wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 2000; 74:11456-11463.
65. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6:973-985.
66. Hermans WT, ter Brakke O, Dijkhuisen A, Sonnemans MA, Grimm D, Kleinschmidt JA, Verhaagen J. Purification of recombinant adeno-associated virus by iodixonal gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther l999; 10: 1885-1891.
67. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996; 7:507-513.
68. Clark RW, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum Gene Ther 1999; 10:1031-1039.
69. Gao G, Gu G, Burnhan MS, Huang J, Chirmule N, Joshi B, Yu Q-C, Marsh JA, Conceicao CM, Wilson JM. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 2000; 11:2079-2091.
70. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus inducible rep and cap genes allows fore infectivity titration of adeno-associated virus vectors. Gene Ther 1996; 3:1124-1132.
71. Atkinson EM, Debelak DJ, Hart LA, Reynolds TC. A high-throughput hybridization method for titer determination of viruses ands gene therapy vectors. Nucleic Acids Res 1998; 26; 2821-2823.
72. Debelak DJ, Fisher J. Iuliano S, Sesholtz D, Sloane DL, Atkinson EM. Cation exchange high-performance liquid chromatography of recombinant adeno-associ-ated virus type 2. J Chromatogr 2000; 740:195-202.
73. Russell DW, Alexander IE, Miller AD. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994; 91:8915-8919.
74. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11:517-521.
75. Podsakoff G, Wong KK, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus based vectors. J Virol 1994; 68:5656-5666.
76. Ferrari FK, Samulski T, Shenk T, Samulski R. Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70:3227-3234.
77. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM: Transduction with recombinant adeno-associated virus vectors for gene therapy is limited by leading strand synthesis. J Virol 1996; 70:520-532.
78. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. J Virol 1995; 92: 5719-5723.
79. Flotte, TR, Afione, SA, Solow, R, McGrath, SA, Conrad, C, Zeitlin, PL, Guggino, WB Carter, BJ. In vivo delivery of adeno-associated vectors expressing the cystic fibrosis transmembrane conductance regulator to the airway epithelium. Proc Natl Acad Sci USA 1993; 93:10163-10617.
80. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, Fee-Maki M, Barrazza-Ortiz X, Adams R, Askin FB, Carter BJ, Guggino WB, Flotte TR. Safety of singledose administration of an adeno-associated virus (AAV-CFTR) vector in the primate lung. Gene Ther 1996; 3:658-668.
81. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff D, O’Malley KL, During M. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8:148-154.
82. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997; 144:113-124.
83. Snyder RO, Spratt SK, Lagarde C, Bohl C, Kaspar B, Sloan B, Cohen LK, Danos O. Efficient and stable adeno-associated virus-mediated transduction of the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8:1891-1900.
84. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 116:270-275.
85. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72:1438-1445.
86. 5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5:78-82.
87. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-asociated virus 2. Nat Med 1999; 5:71-77.
88. Goldman M, Su Q, Wilson JM. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. Gene Ther 1996; 3:811-818.
89. Duan D, Yue Y, Yan Y, McCray PB, Engelhardt JF. Polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epi-thelia. Human Gene Ther 1998; 9:2761-2776.
90. Miramatsu S, Mizukami H, Young N, Brown KE. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996; 221: 208-217.
91. Chiorini J, Yang L, Liu Y, Safer B, Kotin R. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73:1309-1319.
92. Xiao W, Chirmule N. Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73:3994-4003.
93. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823-6833.
94. Rutledge EA, Halbert CL, Russell DW. Infectious clones of vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
95. Davidson B, Stein C, Heth J. Martins L, Kotin R, Derksen T, Zabner J, Rhodes A, Chiorini J. Recombinant adeno-associated virus type 2, 4 and 5 vectors: transduction of variant cell types and regions in mammalian central nervous system. Proc Natl Acad Sci UsA 2000; 97:3428-3432.
96. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. moi Ther 2000; 2:619-623.
97. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999; 265:274-285.
98. Girod A, Ried M, Wobus M, Lahm H, Leike K, Kleinschmidt J, Delage G, Haller M. genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5:1052-1056.
99. Bartlett JS. Prospects for the development of targeted adeno-asociated virus (AAV) vectors. Tumor Target 1999; 4:143-149.
100. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD. Epitope mapping of human adeno-associated virus type 2 neutralizing anti-antibodies: implications for gene therapy and structure. J Virol 2000; 74:1761-1766.
101. Rabinowitz JE, Samulski RJ. Building a better vector: manipulation of AAV virions. Virology 2000; 278:301-308.
102. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Fjerkol T, Flotte T, Muzyczka N. Analysis of the adeno-asociated type 2 (AAV2) capsid gene and construction of AAV vectors with altered tropism. J Virol 2000; 74:8635-8647.
103. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JE. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73:10371-10376.
104. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated and adeno-associated virus vectors. J Virol 2000; 74:2777-2785.
105. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteo-some degradation. J Virol 2000; 75:1824-1833.
106. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endo-cytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Racl and phosphatidylinositol-3 kinase activation. Virology 2000; 74:9184-9196.
107. Duan D, Yue Y, Yan Z, Yamg J, Engelhardt JE. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105:1573-1587.
108. Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Gug-gino WB, Cutting GR, Carter BJ, Flotte TR. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70:3235-3241.
109. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, Kay MA. The kinetics of rAAV integration into the liver. Nat Genet 1998; 19:13-14.
110. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF. Circular intermediates of recombinant adeno-associated virus have defined struc tural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72:8568-8577.
111. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Ye Y, Lester R, Yang J, Fisher KJ, Engelhardt JF. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 orf6 and E2A gene expression. J Virol 1999; 73:161-169.
112. Nakai H, Storm TA, Lay MA. Recruitment of single-stranded recombinant adeno-associated vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74:9451-9463.
113. Duan D, Yan Z, Yue Y, Engelhardt JE. Structural analysis of adeno-associated virus transduction circular intermediates. Virology 1999; 261:8-14.
114. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JE. Concatemerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73:9468-9477.
115. Sanlioglu S, Benson P, Engelhardt JE. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 2000; 268;68-78.
116. Song S, Laipis P, Berns KI, Flotte T. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 2000; 98:4084-4088.
117. Duan D, Yue Y, Yan Z, Engelhardt. A new dual vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000; 6:595-598.
118. Yan Z, Zhang Y, Duan D, Engelhardt JE. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000; 97: 6716-6721.
119. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000; 18:527-532.
120. Sun L, Li J, Xiao X. Overcoming adeno-associated virus size limitation through viral DNA heterodimerization. Nat Med 2000; 6:599-602.
121. Chirmule N, Xiao W, Truneh A, Schnell M, Hughes JV, Zoltich P. Wilson JM, Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and non-human primate muscle. J Virol 2000; 74:2420-2425.
122. Halbert CL, Standaert TA, Wilson CB, and Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during initial exposure. J Virol 1998; 72:9795-9805.
123. Hernandez YJ, Wang J, Kearns WG, Wiler S, Poirer A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a non-human primate model. J Virol 1999; 73:8549-8558.
124. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T-cell independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1:323-329.
125. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engelmann E. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999; 2: 67-75.
126. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence and readministration. J Virol 1997; 71:5932-5941.
127. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated virus vectors. Hum Gene Ther 1998; 9:477-485.
128. Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC, Carter BJ, Askin FB, Flotte TR, Guggino WB. Repeated delivery of adeno-associated virus vectors to the rabbit airway J Virol 1999; 73:9446-9455.
129. Zhang Y, Chirmule N, Gao G-P, Wilson JM:.CD40-ligand dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J Virol 2000; 74:8003-8010.
130. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72:4212-4223.
131. Manning WC, Paliard X, Zhou S, Bland MP, Lee AY, Hong K, Walker CM, Escobedo JA, Dwarki V. Genetic immunization with adeno-associated virus vectors expressing herpes simplex type2 glycoproteins B and D. J Virol 1997; 71:7960-7962.
132. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McClelland ML, Hogstrom JW, Pasi EJ, Erth HCJ, Herzog RW, High KA. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product Factor IX. Mol Ther 2000; 1:225-231.
133. Egan M, Flotte T, Zeitlin P, Afione S, Solow R, Carter BJ, Guggino WB: Defective regulation of outwardly rectifying Cl-channels by protein kinase A corrected by insertion of CFTR. Nature 1992; 358:581-583.
134. Herzog RW, Hagstrom JN, Jung S-H, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94:5804-5809.
135. Nakai H, Herzog RW, Hagstrom J, Walter J, Kung SH, Yang EY, Tsai SJ, Iwaki Y, Kurtzman G, Fisher KJ, Colosi P, Couto LB, High KA. Adeno-associated viral vector mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998;91:4600-4607.
136. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96:3906-3910.
137. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5:56-63.
138. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhaus KM, and Kay MA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5:64-70.
139. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia dogs by AAV mediated gene therapy in liver. Mol Ther 2000; 1:154-158.
140. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin H-F, Stafford, DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA: Correction of hemophilia B in canine and murine models using recombinant adeno-associated vectors. Nat Med 1999; 5:64-69.
141. Monahan PE, Samulski RJ, Tazelar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5:40-49.
142. Xiao X, Li J, Tsao Y-P, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000; 74:1436-1442.
143. Greelish JD, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, Mercier IM, Desjardins PR, Mitchell MA, Zheng X-G, Leferovich J, Gao G-P, Balice-Gardon RJ, Wilson JM, Stedman HH. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5:439-443.
144. Cordier L, Hack A-A, Scott MO, Barton-Davis ER, Gao G-P, Wilson JM, McNally EM, Sweeney HL. Rescue of skeletal muscles of Y-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther 2000; 1:119-126.